ArriVent Biopharma, Inc. (AVBP)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$12.23-9.34%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · AVBP
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -51.1% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 117 industry peers
AVBP — earnings miss
Dated 2026-05-11
and in the press release furnished as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, or incorporated by reference in any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation langua…
Why it matters: ARR-002 has entered a Phase 1 trial for ovarian and endometrial cancer. Patient data will test the new dual-target approach in people.
Watch forThe Phase 1 update reports tumor responses and no new safety issue that limits dosing.
Also watch forThe trial reports no tumor responses, a serious safety issue, or a pause in dosing.
Why it matters: ArriVent has no reported revenue and posted a $52.7 million operating loss in 2026 Q2. The next report can show whether cash use is rising.
Worry ifThe November 9 report shows an operating loss above $52.7 million for the quarter. It reports no revenue.
Less concerning ifThe operating loss is $52.7 million or less, or the report shows revenue.
Why it matters: ALPACCA tests firmonertinib in first-line EGFR PACC lung cancer. Enrollment and trial progress will show whether this lead program stays on track.
Supportive ifThe company reports that ALPACCA enrollment continues. It gives a trial update with no pause or delay.
Worry ifThe company reports a pause in ALPACCA enrollment, a trial delay, or a study change that slows progress.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$165 on $10,000 · ±1.6% | How much price usually moves either way. |
| Bad day | $544 loss on $10,000 · 5.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,480 loss on $10,000 · 64.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.